• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Ahmedabad, Aug 30

Zydus Cadila has filed an Investigational New Drug (IND) application for seeking the Drug Controller-General of India’s (DCGI) permission to conduct clinical trials for its New Molecular Entity (NME), ZYH7, a drug candidate for treating metabolic disorders. The 230 scientists at Zydus Research Centre, set up in the year 2000,have focused on metabolic disorders, diabetes and obesity, cardiovascular disorders and pain and inflammatory disorders, a release said. – Our Bureau

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Atlas sets up materials exposing site near Chennai

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line